Search

Displaying results 8041 - 8050 of 9686 in total
  1. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Oxyphenisatin

    go.drugbank.com/drugs/DB04823
    ApprovedWithdrawn

    A laxative that undergoes enterohepatic circulation. It may cause jaundice.

  3. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    Methaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. … Its use peaked in the early 1970s as a hypnotic, sedative, and muscle relaxant commonly used for insomnia.

  4. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

  5. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.

  6. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. … Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  8. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  9. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that ...

  10. Drug

    Tirapazamine

    go.drugbank.com/drugs/DB04858
    Investigational

    This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia.